A scientific study has proven that dietary supplements can prevent hereditary cancer

Resistant starch has been shown to have a major preventive effect on a wide range of cancers in people at hereditary risk.

Can a banana a day prevent cancer?

A major preventive effect of resistant starch on a wide range of cancers was shown in a trial conducted in people with a hereditary risk. Resistant starch can be found in a variety of foods, including oats, breakfast cereals, cooked and chilled pasta or rice, beans and peas, and some green bananas.

An international trial found that regular doses of resistant starch, taken for an average of two years, had no effect on colon cancer but reduced cancers in other parts of the body by more than half. This effect was particularly evident for cancers of the stomach, stomach, biliary tract, pancreas, and duodenum. The trial – called CAPP2 – involved nearly 1,000 Lynch syndrome patients worldwide.

In addition, the surprising effect lasted for 10 years after stopping the use of the supplement.

The study is a planned double-blind 10-year follow-up of 369 participants with up to 20 years of comprehensive national cancer registry data. The study was carried out by experts from the Universities of Newcastle and Leeds and published on 25 July 2022. Cancer Prevention ResearchJournal of the American Association for Cancer Research.

Previous research published as part of the same trial showed that aspirin reduced colon cancer by 50%.

“We found that resistant starch reduces the range of cancer by 60%. The effect was most pronounced in the upper intestine,” explained John Mathers, professor of human nutrition at Newcastle University. “This is important because upper GI tract cancers are difficult to diagnose and often go undetected early.

“Resistant starch powder can be taken as a supplement and occurs naturally in beans, peas, oats and other starchy foods. The dose used in the trial is equivalent to eating a daily banana; Until they are overripe and soft, the starch in bananas does not break down and can reach the gut and change the type of bacteria that live there.

“Resistant starch is a type of carbohydrate that isn’t absorbed in your small intestine. Instead, it ferments in your colon and feeds beneficial gut bacteria—it acts like dietary fiber in your digestive system. This type of starch has several health benefits and fewer calories than regular starch.” Yes.By changing the bacterial metabolism of bile acids, resistant starch is thought to reduce the development of cancer and reduce the types of bile acids that can harm our bodies.[{” attribute=””>DNA and eventually cause cancer. However, this needs further research.”

Professor Sir John Burn, from Newcastle University and Newcastle Hospitals NHS Foundation Trust who ran the trial with Professor Mathers, said: “When we started the studies over 20 years ago, we thought that people with a genetic predisposition to colon cancer could help us to test whether we could reduce the risk of cancer with either aspirin or resistant starch.

“Patients with Lynch syndrome are high risk as they are more likely to develop cancers so finding that aspirin can reduce the risk of large bowel cancers and resistant starch other cancers by half is vitally important.

“Based on our trial, NICE now recommends Aspirin for people at high genetic risk of cancer, the benefits are clear – aspirin and resistant starch work.”

Long term study

Nearly 1000 participants between 1999 and 2005 began either taking resistant starch in a powder form every day for two years or aspirin or a placebo.

At the end of the treatment stage, there was no overall difference between those who had taken resistant starch or aspirin and those who had not. However, the research team anticipated a longer-term effect and designed the study for further follow-up.

There were just 5 new cases of upper GI cancers among the 463 participants who had taken the resistant starch compared with 21 among the 455 who were on the placebo in the period of follow-up.

The team is now leading the international trial, CaPP3, with more than 1,800 people with Lynch syndrome enrolled to look at whether smaller, safer doses of aspirin can be used to help reduce the cancer risk.

Reference: “Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up” by John C. Mathers, Faye Elliott, Finlay Macrae, Jukka-Pekka Mecklin, Gabriela Möslein Fiona E. McRonald, Lucio Bertario, D. Gareth Evans, Anne-Marie Gerdes, Judy W.C. Ho, Annika Lindblom, Patrick J. Morrison, Jem Rashbass, Raj S. Ramesar, Toni T. Seppälä, Huw J.W. Thomas, Harsh J. Sheth, Kirsi Pylvänäinen, Lynn Reed, Gillian M. Borthwick, D. Timothy Bishop and John Burn on behalf of the CAPP2 Investigators, 25 July 2022, Cancer Prevention Research.
DOI: 10.1158/1940-6207.CAPR-22-0044

The research is funded by Cancer Research UK, the European Commission, Medical Research Council, and the National Institute for Health Research.

Leave a Comment

Your email address will not be published.